The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berman, R. M.
Right arrow Articles by Lotze, M. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berman, R. M.
Right arrow Articles by Lotze, M. T.

The Journal of Immunology, Vol 157, Issue 1 231-238, Copyright © 1996 by American Association of Immunologists

ARTICLES

Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice

RM Berman, T Suzuki, H Tahara, PD Robbins, SK Narula and MT Lotze
Department of Molecular Genetics and Biochemistry, School of Medicine, University of Pittsburgh, PA 15261, USA.

Cellular IL-10 (cIL-10), the collective term for human and murine IL- 10, has both stimulatory and inhibitory effects on diverse cell types, including costimulation of T cell proliferation, chemoattraction of CD8+ T cells, and stimulation of lymphokine-activated killer cell activity. Human IL-10 (hIL-10) differs from its EBV homolog viral IL-10 (vIL-10) by only 16% at the amino acid level; however, vIL-10 shares with cIL-10 predominantly inhibitory effects, such as macrophage deactivation. We administered cIL-10 systemically to mice bearing established (day 7) sarcomas, melanomas, or colorectal carcinomas. At high doses (20 to 60 micrograms/day x 7 days), cIL-10 induced rejection of tumors, delaying tumor outgrowth or resulting in complete cure. Sublethal irradiation (500 rad) of mice prior to tumor inoculation abrogated the IL-10 effect. Cured mice were immune to subsequent rechallenge with 10-fold higher inoculation with the same, but not a different, tumor. IL-12 also has potent antitumor activity and interacts with IL-10 in both complementary and antagonistic ways; co- administration of both cytokines resulted in additive antitumor activity. To compare cIL-10 vs vIL-10 effects in vivo, we engineered CL8-1 melanoma transfectants bearing the vIL-10 or the murine IL-10 (mIL-10) gene. Local secretion of mIL-10 induced rejection of tumors, while vIL-10 resulted in accelerated outgrowth. Subsequent systemic administration of cIL-10 to mice bearing vIL-10-transduced tumors completely reversed the local suppressive effects, leading to rejection, suggesting distinct pathways for cIL-10 and vIL-10 effects. That cIL-10 can stimulate the acquisition of an effective, specific, and long-lived antitumor immune response in murine models and can reverse the local immunosuppressive effects of vIL-10 indicates a potential role for cIL-10 administration in the biologic therapy of cancer and suggests a broader interpretation of IL-10 biology.


This article has been cited by other articles:


Home page
 Eur Respir JHome page
L. M. Montuenga and R. Pio
Tumour-associated macrophages in nonsmall cell lung cancer: the role of interleukin-10
Eur. Respir. J., October 1, 2007; 30(4): 608 - 610.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Kaiga, M. Sato, H. Kaneda, Y. Iwakura, T. Takayama, and H. Tahara
Systemic Administration of IL-23 Induces Potent Antitumor Immunity Primarily Mediated through Th1-Type Response in Association with the Endogenously Expressed IL-12
J. Immunol., June 15, 2007; 178(12): 7571 - 7580.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
S. Mocellin, F. M. Marincola, and H. A. Young
Interleukin-10 and the immune response against cancer: a counterpoint
J. Leukoc. Biol., November 1, 2005; 78(5): 1043 - 1051.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Beckebaum, X. Zhang, X. Chen, Z. Yu, A. Frilling, G. Dworacki, H. Grosse-Wilde, C. E. Broelsch, G. Gerken, and V. R. Cicinnati
Increased Levels of Interleukin-10 in Serum from Patients with Hepatocellular Carcinoma Correlate with Profound Numerical Deficiencies and Immature Phenotype of Circulating Dendritic Cell Subsets
Clin. Cancer Res., November 1, 2004; 10(21): 7260 - 7269.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. E. Erdman, V. P. Rao, T. Poutahidis, M. M. Ihrig, Z. Ge, Y. Feng, M. Tomczak, A. B. Rogers, B. H. Horwitz, and J. G. Fox
CD4+CD25+ Regulatory Lymphocytes Require Interleukin 10 to Interrupt Colon Carcinogenesis in Mice
Cancer Res., September 15, 2003; 63(18): 6042 - 6050.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. S. Yang and E. C. Lattime
Tumor-induced Interleukin 10 Suppresses the Ability of Splenic Dendritic Cells to Stimulate CD4 and CD8 T-Cell Responses
Cancer Res., May 1, 2003; 63(9): 2150 - 2157.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J.-C. Soria, C. Moon, B. L. Kemp, D. D. Liu, L. Feng, X. Tang, Y.-S. Chang, L. Mao, and F. R. Khuri
Lack of Interleukin-10 Expression Could Predict Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer
Clin. Cancer Res., May 1, 2003; 9(5): 1785 - 1791.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
A.-F. Petit-Bertron, C. Fitting, J.-M. Cavaillon, and M. Adib-Conquy
Adherence influences monocyte responsiveness to interleukin-10
J. Leukoc. Biol., January 1, 2003; 73(1): 145 - 154.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. G. Lee, R. J. Homer, L. Cohn, H. Link, S. Jung, J. E. Craft, B. S. Graham, T. R. Johnson, and J. A. Elias
Transgenic Overexpression of Interleukin (IL)-10 in the Lung Causes Mucus Metaplasia, Tissue Inflammation, and Airway Remodeling via IL-13-dependent and -independent Pathways
J. Biol. Chem., September 13, 2002; 277(38): 35466 - 35474.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Dorsey, N. Kundu, Q. Yang, C. S. Tannenbaum, H. Sun, T. A. Hamilton, and A. M. Fulton
Immunotherapy with Interleukin-10 Depends on the CXC Chemokines Inducible Protein-10 and Monokine Induced by IFN-{gamma}
Cancer Res., May 1, 2002; 62(9): 2606 - 2610.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. M. Segal, D. D. Glass, and E. M. Shevach
Cutting Edge: IL-10-Producing CD4+ T Cells Mediate Tumor Rejection
J. Immunol., January 1, 2002; 168(1): 1 - 4.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S.-i. Fujii, K. Shimizu, T. Shimizu, and M. T. Lotze
Interleukin-10 promotes the maintenance of antitumor CD8+ T-cell effector function in situ
Blood, October 1, 2001; 98(7): 2143 - 2151.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
S. Kawamoto, Y. Nitta, F. Tashiro, A. Nakano, E. Yamato, H. Tahara, K. Tabayashi, and J.-i. Miyazaki
Suppression of Th1 cell activation and prevention of autoimmune diabetes in NOD mice by local expression of viral IL-10
Int. Immunol., May 1, 2001; 13(5): 685 - 694.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. A. Grimm, C. M. Smid, J. J. Lee, C.-H. Tseng, O. Eton, and A. C. Buzaid
Unexpected Cytokines in Serum of Malignant Melanoma Patients during Sequential Biochemotherapy
Clin. Cancer Res., October 1, 2000; 6(10): 3895 - 3903.
[Abstract] [Full Text]

Home page
 BloodHome page
L. Cervenak, L. Morbidelli, D. Donati, S. Donnini, T. Kambayashi, J. L. Wilson, H. Axelson, E. Castanos-Velez, H.-G. Ljunggren, R. D. W. Malefyt, et al.
Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10
Blood, October 1, 2000; 96(7): 2568 - 2573.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. D. Santin, P. L. Hermonat, A. Ravaggi, S. Bellone, S. Pecorelli, J. J. Roman, G. P. Parham, and M. J. Cannon
Interleukin-10 Increases Th1 Cytokine Production and Cytotoxic Potential in Human Papillomavirus-Specific CD8+ Cytotoxic T Lymphocytes
J. Virol., May 15, 2000; 74(10): 4729 - 4737.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
L.-F. Lee, R. P. Hellendall, Y. Wang, J. S. Haskill, N. Mukaida, K. Matsushima, and J. P.-Y. Ting
IL-8 Reduced Tumorigenicity of Human Ovarian Cancer In Vivo Due to Neutrophil Infiltration
J. Immunol., March 1, 2000; 164(5): 2769 - 2775.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. M. Minter, J. E. Rectenwald, K. Fukuzuka, C. L. Tannahill, D. La Face, V. Tsai, I. Ahmed, E. Hutchins, R. Moyer, E. M. Copeland III, et al.
TNF-{alpha} Receptor Signaling and IL-10 Gene Therapy Regulate the Innate and Humoral Immune Responses to Recombinant Adenovirus in the Lung
J. Immunol., January 1, 2000; 164(1): 443 - 451.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
S. D. Jayasena
Aptamers: An Emerging Class of Molecules That Rival Antibodies in Diagnostics
Clin. Chem., September 1, 1999; 45(9): 1628 - 1650.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
M. Adib-Conquy, A.-F. Petit, C. Marie, C. Fitting, and J.-M. Cavaillon
Paradoxical priming effects of IL-10 on cytokine production
Int. Immunol., May 1, 1999; 11(5): 689 - 698.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Steinbrink, H. Jonuleit, G. Muller, G. Schuler, J. Knop, and A. H. Enk
Interleukin-10-Treated Human Dendritic Cells Induce a Melanoma-Antigen-Specific Anergy in CD8+ T Cells Resulting in a Failure to Lyse Tumor Cells
Blood, March 1, 1999; 93(5): 1634 - 1642.
[Abstract] [Full Text] [PDF]

Home page
 Innate ImmunityHome page
J.-M. Cavaillon, M. Adib-Conquy, C. Marie, and C. Fitting
Hyporesponsiveness in leukocytes in sepsis: in vitro models reveal paradoxical effects of IL-10
Innate Immunity, February 1, 1999; 5(1-2): 81 - 85.
[Abstract] [PDF]

Home page
 BloodHome page
C. Rieser, C. Papesh, M. Herold, G. Bock, R. Ramoner, H. Klocker, G. Bartsch, and M. Thurnher
Differential Deactivation of Human Dendritic Cells by Endotoxin Desensitization: Role of Tumor Necrosis Factor-alpha and Prostaglandin E2
Blood, May 1, 1998; 91(9): 3112 - 3117.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1996 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1996 by The American Association of Immunologists, Inc. All rights reserved.